FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.:	10/627,413	ATTY. DOCKET NO.:	C1039.70079US00
INFORMATION DISCLOSURE	FILING DATE:	July 25,2003	CONFIRMATION NO.:	3204
STATEMENT BY APPLICANT	APPLICANT:	Krieg et al.		
Strange to lot 11	GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

DEC 1 7 2007

U.S. PATENT DOCUMENTS

Examiner's Sile	U.S. Patent Docu		Name of Patentee or Applicant of Cited	Date of Publication or Issue
Examiner's No.	Number Kind Code		Document	of Cited Document MM-DD-YYYY
	5,457,189		Crooke et al.	10-10-1995
	5,567,604		Rando et al.	10-22-1996
	5,665,580		Crooke et al.	09-09-1997
	5,681,944		Crooke et al.	10-28-1997
	5,858,987	<u> </u>	Beer-Romero et al.	01-12-1999
	6,221,882	B1	Macfarlane	04-24-2001
	6,399,630	B1	Macfarlane	06-04-2002
	6,479,504	B1	Macfarlane et al.	11-12-2002
	6,521,637	B2	Macfarlane	02-18-2003
	6,589,940	B1	Raz et al.	07-08-2003
	6,727,230	B1	Hutcherson et al.	04-27-2004
	6,821,957	B1	Krieg et al.	11-23-2004
	6,943,240	B2	Bauer et al.	09-13-2005
	6,949,520	B1	Hartmann et al.	09-27-2005
	7,001,890	B1	Wagner et al.	02-21-2006
	7,223,741	B2	Krieg	05-29-2007
	7,271,156	B2	Krieg et al.	07-18-2007
	2001-0044416	A1	McCluskie et al.	11-22-2001
	2002-0086839	A1	Raz et al.	07-04-2002
	2002-0091097	Al	Bratzler et al.	07-11-2002
	2002-0164341	A1	Davis et al.	11-07-2002
	2002-0165178	Al	Schetter et al	11-07-2002
	2002-0198165	A1	Bratzler et al.	12-26-2002
	2003-0026782	Al	Krieg	02-02-2003
	2003-0026801	A1	Weiner et al.	02-06-2003
	2003-0050268	Al	Krieg et al.	03-13-2003
	2003-0055014	Al	Bratzler	03-20-2003
	2003-0091599	A1	Davis et al.	05-15-2003
	2003-0100527	A1	Krieg et al.	05-29-2003
	2003-0139364	Al	Krieg et al.	07-24-2003
	2003-0148316	Al	Lipford et al.	08-07-2003
	2003-0148976	Al	Krieg et al.	08-07-2003

EXAMINER:	DATE CONSIDERED:

^{*}EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO 1440/A and R (modified PTO/SR/08)				APPLICATION NO.:	10/627,413	ATTY. DOCKET N	NO.: C1039.70079US00
FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE:	July 25,2003	CONFIRMATION	NO.: 3204	
			APPLICANT:	Krieg et al.			
Sheet	2	of	11	GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

	2003-0166001	Al	Lipford	09-04-2003
	2003-0181406	Al	Schetter et al.	09-25-2003
	2003-0191079	Al	Krieg et al.	10-09-2003
	2003-0224010	Al	Davis et al.	12-04-2003
	2003-0232074	Al	Lipford et al.	12-18-2003
	2003-0232856	Al	Macfarlane	12-18-2003
	2003-0232780	Al	Carson et al.	12-18-2003
· · · · · · · · · · · · · · · · · · ·	2004-0006010	Al	Carson et al.	01-08-2004
	2004-0006034	Al	Raz et al.	01-08-2004
	2004-0009949	Al	Krieg	01-15-2004
	2004-0030118	Al	Wagner et al.	02-12-2004
	2004-0053880	Al	Krieg	03-18-2004
	2004-0067902	A9	Bratzler et al.	04-08-2004
	2004-0067905	Al	Krieg	04-08-2004
	2004-0087534	Al	Krieg et al.	05-06-2004
	2004-0087538	Al	Krieg et al.	05-06-2004
	2004-0092472	Al	Krieg	05-13-2004
-	2004-0106568	Al	Krieg et al.	06-03-2004
	2004-0115219	Al	Ahn et al.	06-17-2004
	2004-0131628	Al	Bratzler et al.	07-08-2004
	2004-0132685	A1	Krieg et al.	07-08-2004
	2004-0142469	Al	Krieg et al.	07-22-2004
	2004-0143112	A1	Krieg et al.	07-22-2004
	2004-0147468	Al	Krieg et al.	07-29-2004
	2004-0152649	Al	Krieg	08-05-2004
	2004-0152656	Al	Krieg et al.	08-05-2004
-	2004-0152657	Al	Krieg et al.	08-05-2004
	2004-0162258	Al	Krieg et al.	08-19-2004
	2004-0162262	Al	Krieg et al.	08-19-2004
	2004-0167089	Al	Krieg et al.	08-26-2004
	2004-0171150	Al	Krieg et al.	09-02-2004
	2004-0171571	Al	Krieg et al.	09-02-2004
	2004-0181045	Al	Krieg et al.	09-16-2004
	2004-0198680	Al	Krieg	10-07-2004
	2004-0198688	Al	Krieg et al.	10-07-2004
	2004-0229835	Al	Krieg et al.	11-18-2004

EXAMINER:	DATE CONSIDERED:
·	

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.:	10/627,413	ATTY. DOCKET	NO.: C1039.70079US00
INFORMATION DISCLOSURE			FILING DATE:	July 25,2003	CONFIRMATION	NO.: 3204	
STATEMENT BY APPLICANT		APPLICANT:	Krieg et al.	•			
Sheet	3	of	11	GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

2004-0234512	A1	Wagner et al.	11-25-2004
2004-0235770	Al	Davis et al.	11-25-2004
2004-0235774	Al	Bratzler et al.	11-25-2004
 2004-0235777	Al	Wagner et al.	11-25-2004
2004-0235778	Al	Wagner et al.	11-25-2004
 2004-0266719	A1	McCluskie et al.	12-30-2004
2005-0004061	A1	Krieg et al.	01-06-2005
2005-0004062	A1	Krieg et al.	01-06-2005
2005-0009774	Al	Krieg et al.	01-13-2005
 2005-0031638	A1	Dalemans et al.	02-10-2005
2005-0032734	A1	Davis et al.	02-10-2005
2005-0032736	A1	Krieg et al.	02-10-2005
 2005-0037403	A1	Krieg et al.	02-17-2005
2005-0037985	A1	Krieg et al.	02-17-2005
2005-0043529	Al	Davis et al.	02-24-2005
2005-0049215	A1	Krieg et al.	03-03-2005
2005-0049216	A1	Krieg et al.	03-03-2005
 2005-0054601	A1	Wagner et al.	03-10-2005
2005-0054602	A1	Krieg et al.	03-10-2005
2005-0059619	Al	Krieg et al.	03-17-2005
2005-0059625	A1	Krieg et al.	03-17-2005
2005-0070491	A1	Krieg et al.	03-31-2005
2005-0075302	Al	Hutcherson et al.	04-07-2005
2004-0092468	Al	Schwartz et al.	05-13-2004
2005-0100983	Al	Bauer et al.	05-12-2005
2005-0101554	A1	Krieg et al.	05-12-2005
2005-0101557	A1	Krieg et al.	05-12-2005
2005-0119273	A1	Lipford et al.	06-02-2005
 2005-0123523	Al	Krieg et al.	06-09-2005
2005-0130911	A1	Uhlmann et al.	06-16-2005
 2005-0148537	Al	Krieg et al.	07-07-2005
2005-0169888	Al	Hartman et al.	08-04-2005
 2005-0171047	Al	Krieg et al.	08-04-2005
2005-0181422	Al	Bauer et al.	08-18-2005
2005-0182017	Al	Krieg	08-18-2005
 2005-0197314	Al	Krieg et al.	09-08-2005

EXAMINER:	DATE CONSIDERED:

^{*} EXAMINER: Initial if reference considered, whether or noticitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.:	10/627,413	ATTY. DOCKET N	IO.: C1039.70079US00
				FILING DATE:	July 25,2003	CONFIRMATION	NO.: 3204
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT:	Krieg et al.			
		ı ı	-	GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le
Sheet	4	of	11				

	2005-0215501	A1	Lipford et al.	09-29-2005
	2005-0233995	A1	Krieg et al.	10-20-2005
	2005-0233999	A1	Krieg et al.	10-20-2005
	2005-0239732	A1	Krieg et al.	10-27-2005
· ·	2005-0239733	A1	Jurk et al.	10-27-2005
	2005-0239734	A1	Uhlmann et al.	10-27-2005
	2005-0239736	A1	Krieg et al.	10-27-2005
	2005-0244379	A1	Krieg et al.	11-03-2005 .
	2005-0244380	A1	Krieg et al.	11-03-2005
	2005-0245477	A1	Krieg et al.	11-03-2005
	2005-0250726	Al	Krieg et al.	11-10-2005
	2005-0256073	A1	Lipford et al.	11-17-2005
	2005-0267064	A1	Krieg et al.	12-01-2005
	2005-0277604	Al	Krieg et al.	12-15-2005
	2005-0277609	A1	Krieg et al.	12-15-2005
	2006-0003955	A1	Krieg et al.	01-05-2006
	2006-0003962	A1	Ahluwalia et al.	01-05-2006
	2006-0019916	A1	Krieg et al.	01-26-2006
	2006-0019923	Al	Davis et al.	01-26-2006
	2006-0058251	A1	Krieg et al.	03-16-2006
	2006-0089326	A1	Krieg et al	04-27-2006
	2006-0094683	A1	Krieg et al.	05-04-2006
	2006-0140875	A1	Krieg et al.	06-29-2006
	2006-0154890	A1	Bratzler et al.	07-13-2006
	2006-0172966	A1	Lipford et al.	08-03-2006
	2006-0188913	A1	Krieg et al.	08-24-2006
	2006-0211639	A1	Bratzler et al.	09-21-2006
	2006-0211644	A1	Krieg et al.	09-21-2006
	2006-0229271	A1	Krieg et al.	10-12-2006
	2006-0241076	Al	Uhlmann et al.	10-26-2006
	2006-0246035	Al	Ahluwalia et al.	11-02-2006
	2006-0286070	Al	Hartmann et al.	12-21-2006
	2006-0287263	· A1	Davis et al.	12-21-2006
	2007-0009482	Al	Krieg et al.	01-11-2007
	2007-0010470	A1	Krieg et al.	01-11-2007
	2007-0037767	A1	Bratzler et al.	02-15-2007

EXAMINER:	DATE CONSIDERED:

^{*}EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-	1440/A an	d B (modifie	d PTO/SB/08)	APPLICA	ATION NO.: 10/627,413	ATTY. DOC	KET NO.: C1039.	70079US00
•			·	FILING	DATE: July 25,2003	CONFIRMA	TION NO.: 3204	
		-	CLOSURE PLICANT	APPLICA	ANT: Krieg et al.			
Sheet	Sheet 5 of 11				ART UNIT: 1648	EXAMINER	: Emily	M. Le
Silect			11					
		2007-006	5467	A1	Krieg et al.		03-22-2007	
		2007-006		Al	Krieg et al.		03-22-2007	
		2007-006		Al	Krieg et al.		03-22-2007	
		2007-007	8104	A1	Krieg et al.		04-05-2007	
		2007-012	9320	A9	Davis et al.		06-07-2007	
		2007-014	2315	Al	Forsbach et al.		06-21-2007	
		2007-018	4465	Al	Wagner et al.		08-09-2007	
		2007-020	2128	A1	Krieg et al.	 	08-30-2007	
		2007-022	4210	A1	Krieg et al.		09-27-2007	
		2007-023	2622	Al	Lipford et al.		10-04-2007	
				FOREIC	IN DATEME DOCUMENTO			
		For	eign Patent Docun		ON PATENT DOCUMENTS		Date of	
Examiner's Initials #	Cite No.	Office/ Country	Number	Kind Code	Name of Patentee or Applicant of Cite Document		Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
	*	wo	99/56755	Al	University of Iowa Research I	Foundation	11-11-1999	
	*	wo	00/06588	A1	University of Iowa Research I	· · · · · · · · · · · · · · · · · · ·	02-10-2000	
	*	WO	00/14217	A2	CPG Immunopharmaceuticals	GMBH	03-16-2000	
	*	WO	00/67023	A1	CPG Immunopharmaceuticals	GMBH	11-09-2000	
	*	WO	2004/007743	A2	Coley Pharmaceutical GMBH		01-22-2004	
	*	wo	2004/026888	A2	Coley Pharmaceutical GMBH		04-01-2004	
	*	wo	2004/094671	A2	Coley Pharmaceutical GMBH		11-04-2004	
	*	wo	2006/080946	A2	Coley Pharmaceutical GMBH		08-03-2006	
	*	WO	2007/031877	A2	Coley Pharmaceutical GMBH		03-22-2007	
	*	WO	2007/038720	A2	Coley Pharmaceutical GMBH		04-05-2007	
		•			PATENT LITERATURE DOCL			
Examiner's Initials #	Cite No	(book, ma	agazine, journal, s	erial, sympo city	AL LETTERS), title of the article (visium, catalog, etc.), date, page(s), viand/or country where published.	olume-issue nui	mber(s), publisher,	Translation (Y/N)
	*	Press Rele Strategy".			Pharmaceutical Group Updates	Hepatitis C D	rug Development	
	*	Press Rele Clinical T Cell Lung	rials for PF-351	"Coley Ph 2676 Com	armaceutical Group Announces bined with Cytotoxic Chemothe	Pfizer's Disco	ontinuation of ced Non Small	
	*	AGRAW		inal chemis	stry and therapeutic potential of	CpG DNA. Ti	rends Mol Med.	
	*				nctions in vitro and in vivo to inform Cytokine Res. 1997 Dec;17(DNA-induced	
EXAMINER:					DATE CONSIDERED	:		

^{*}EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO)-1449/A and B (n	nodified	I PTO/SB/08)	APPLICATION NO.:	10/627,413	ATTY. DOCKET NO.: C1039.70079US00		
	•		•	FILING DATE:	July 25,2003	CONFIRMATION	NO.: 3204	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT:	Krieg et al.				
				GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le	
Sheet	6	of	11	GROOF ART OWN.	1010	DA WINDA	Dinny W. De	

*	BRANDA et al., B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin Immunol Immunopathol. 1996 May;79(2):115-21.	
*	CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol. 1997 Aug;84(2):185-93.	
*	COSSUM et al., Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther. 1993 Dec;267(3):1181-90.	
*	COWSERT et al., In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrob Agents Chemother. 1993 Feb;37(2):171-7.	
	FIELDS et al., Fields' Virology. 2001;1:1153.	
*	HSIEH et al., Incorporation of CpG oligodeoxynucleotide fails to enhance the protective efficacy of a subunit vaccine against Mycobacterium tuberculosis. Vaccine. 2004 Jan 26;22(5-6):655-9.	
*	KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose. Jpn J Med Sci Biol. 1990 Oct;43(5):171-82.	
*	KOVARIK et al., CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol. 1999 Feb 1;162(3):1611-7.	
*	KRIEG et al., Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs. American College of Rheumatology 58 th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl).	
*	KRIEG et al., Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal L. monocytogenes challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996:116.	
*	KRIEG et al., Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge. Vaccines. 1997; 97:77-9.	
*	KRIEG et al., Infection. In: McGraw Hill Book. 1996:242-3.	
*	KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.	
*	KRIEG et al., Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004 Nov-Dec;27(6):460-71.	
*	KRIEG, Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun;5(6):471-84.	
*	KULKARNI et al., Effect of dietary nucleotides on response to bacterial infections. JPEN J Parenter Enteral Nutr. 1986 Mar-Apr;10(2):169-71.	
*	KURAMOTO et al., Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction. Cancer Immunol Immunother. 1992;34(5):283-8.	
*	KURAMOTO et al., Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol. 1992 Jul;14(5):773-82.	

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or noticitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO	O-1449/A and B (m	andifie	d PTO/SB/08)	APPLICATION NO.:	10/627,413	ATTY. DOCKET NO.	: C1039.70079US00
'	PRMATION I		ŕ	FILING DATE:	July 25,2003	CONFIRMATION NO	D.: 3204
	TEMENT BY			APPLICANT:	Krieg et al.		
Sheet	7	of	11	GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

*	KURAMOTO et al., In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. Microbiol Immunol. 1989;33(11):929-40.	
*		
	LIU et al., Recombinant interleukin-6 protects mice against experimental bacterial infection. Infect Immun. 1992 Oct;60(10):4402-6.	
*	PISETSKY et al., Immunological properties of bacterial DNA. Ann N Y Acad Sci. 1995 Nov 27;772:152-63.	
*	RANKIN et al., CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):333-	
	40.	
	RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and	
	autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract 615.	
*	SATOH et al., The study of mechanisms in CpG oligodeoxynucleotides-induced aggravation in murine allergic contact dermititis to 2,4-dinitrofluorobenzene. Fukushima Igaku Zasshi. 2002;52(3):237-50.	
*	SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. J Interferon Cytokine Res. 1996 Oct;16(10):799-803.	
*	STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev. 1994 Summer;4(2):67-9.	· ·· · · · · · · · · · · · · · · · · ·
*	STEIN et al., Non-antisense effects of oligodeoxynucleotides. Antisense Technology. 1997; ch11: 241-64.	
*	STEIN et al., Antisense oligonucleotides as therapeutic agents—is the bullet really magical? Science. 1993 Aug 20;261(5124):1004-12.	
*	THREADGILL et al., Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide. Vaccine. 1998 Jan;16(1):76-82.	
*	WAAG et al., Injection of inactivated phase I Coxiella burnetii increases non-specific resistance to infection and stimulates lymphokine production in mice. Ann N Y Acad Sci. 1990;590:203-14.	
*	YAMAMOTO et al., [Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG] Kekkaku. 1994 Sep;69(9):571-4. Japanese.	Y-Abs
*	ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):495-	
*	Patent Interference No. 105,171. Iowa Preliminary Motion 3 (for judgment based on failure to comply with 35 U.S.C. 135(b)). (Electronically filed, unsigned). June 7, 2004.	
*	Patent Interference No. 105,171. Iowa Preliminary Motion 4 (for judgment of no interference in fact). (Electronically filed, unsigned). June 7, 2004.	
*	Patent Interference No. 105,171. Iowa Preliminary Motion 5 (for judgment based on lack of enablement). (Electronically filed, unsigned). June 7, 2004.	
*	Patent Interference No. 105,171. Iowa Preliminary Motion 6 (for judgment based on lack of adequate written description). (Electronically filed, unsigned). June 7, 2004.	
*	Patent Interference No. 105,171. Iowa Preliminary Motion 7 (motion to redefine interference to designate claims as not corresponding to the Count). (Electronically filed, unsigned). June 7, 2004.	

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO	D-1449/A and B (m	odified	PTO/SB/08)	APPLICATION NO.: 10/627,413		ATTY. DOCKET NO.: C1039.70079US00		
*	RMATION I		,	FILING DATE:	July 25,2003	CONFIRMATION	NO.: 3204	
	TEMENT BY			APPLICANT:	Krieg et al.			
Sheet	8	of	11	GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le	

	*	Patent Interference No. 105,171. Iowa Preliminary Motion 8 (contingent motion to redefine the	
		Count). (Electronically filed, unsigned). June 7, 2004.	-
	*	Patent Interference No. 105,171. Iowa Preliminary Motion 9 (motion for benefit of earlier	
		application). (Electronically filed, unsigned). June 7, 2004.	
	*	Patent Interference No. 105,171. Iowa Preliminary Motion 10 (contingent motion to redefine the	
		interference by adding a continuation application). (Electronically filed, unsigned). July 2, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Opposition 3 (to Iowa	
	İ	Preliminary Motion 3 for judgment under 35 USC 135(b)). September 9, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Opposition 4 (to Iowa	-
		Preliminary Motion 4 for judgment of no interference in fact). September 9, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Opposition 5 (to Iowa	
	485	Preliminary Motion 5 for judgment that UC's claim is not enabled). September 9, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Opposition 6 (to Iowa	
		Preliminary Motion 6 for judgment based on lack of adequate written description). September 9,	
		2004.	
·	*	Patent Interference No. 105,171. Regents of the University of California Opposition 7 (to Iowa	
		Preliminary Motion 7 to redefine the interference). September 9, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Opposition 8 (to Iowa	-
		Preliminary Motion 8 to redefine the Count). September 9, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Response 9 (to Iowa	-
		Contingent Motion 9 for benefit). September 9, 2004.	
-	*	Patent Interference No. 105,171. Regents of the University of California Opposition 10 (to Iowa	
		Contingent Motion 10 to redefine the interference). September 9, 2004.	
	*		
		Patent Interference No. 105,171. Regents of the University of California Opposition 11 (to Iowa	
	*	Contingent Motion 11 to suppress). October 15, 2004.	
	*	Patent Interference No. 105,171. Iowa Reply 3 (in support of Iowa Preliminary Motion 3 for	
	*	judgment under 35 U.S.C. §135(b)) (Electronically filed, unsigned). October 15, 2004.	
	7	Patent Interference No. 105,171. Iowa Reply 4 (in support of Iowa Preliminary Motion for judgment	
		of no interference in fact) (Electronically filed, unsigned). October 15, 2004.	
	*	Patent Interference No. 105,171. Iowa Reply 5 (in support of Iowa Preliminary Motion 5 for	
		judgment that UC's claim 205 is not enabled) (Electronically filed, unsigned). October 15, 2004.	
	*	Patent Interference No. 105,171. Iowa Reply 6 (in support of Iowa Preliminary Motion 6 for	
,		judgment based on lack of adequate written description) (Electronically filed, unsigned). October	
		15, 2004.	
	*	Patent Interference No. 105,171. Iowa Reply 7 (in support of Iowa Preliminary Motion 7 to redefine	
		the interference) (Electronically filed, unsigned). October 15, 2004.	
	*	Patent Interference No. 105,171. Iowa Reply 8 (in support of Iowa Preliminary Motion 8 to redefine	
		the count) (Electronically filed, unsigned). October 15, 2004.	
	*	Patent Interference No. 105,171. Iowa Reply 10 (in support of Iowa Preliminary Motion 10 to	
	*	redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
	7	Patent Interference No. 105,171. Iowa Reply 11 (in support of Iowa Miscellaneous Motion to	
		suppress). (Electronically filed, unsigned). October 18, 2004.	

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO)-1449/A and B (m	odified	1 PTO/SR/08)	APPLICATION NO.: 10/627,413		ATTY. DOCKET NO.: C1039.70079US00		
•	`		,	FILING DATE:	July 25,2003	CONFIRMATION	NO.: 3204	
l	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT:	Krieg et al.				
Sheet	9	of	11	GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le	

*	Patent Interference No. 105,171. Regents of the University of California Preliminary Statement. June 7, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 1 (to designate additional claims of Iowa patent as corresponding to the Count). June 7, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 2 (for judgment based on lack of written description support and introducing new matter). June 7, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 3 (for judgment based on anticipation). June 7, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 4 (for judgment based on obviousness). June 7, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 5 (for judgment based on anticipation). June 7, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 6 (for judgment based on inequitable conduct). June 7, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 7 (for benefit of an earlier application under 37 CFR 1.633(j)). July 2, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 8 (to add additional claims under 37 CFR 1.633(c)(2) and (i)). July 2, 2004.	
*	Amended Claims for Application Number 09/265,191, filed March 10, 1999.	
*	Patent Interference No. 105,171. Iowa Opposition 1 (opposition to motion to designate additional claims as corresponding to the Count) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Iowa Opposition 2 (opposition to motion for judgment based on lack of written description support and introducing new matter) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Iowa Opposition 3 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Iowa Opposition 4 (opposition to motion for judgment based on obviousness) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Iowa Opposition 5 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Iowa Opposition 6 (opposition to motion for judgment based on inequitable conduct) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Iowa Opposition 7 (opposition to motion for benefit of an earlier application under 7 CFR 1.633(j)) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Iowa Opposition 8 (opposition to motion to add additional claims under 37 CFR 1.633 (2) and (i)) (Electronically filed, unsigned). September 9, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Reply 1 (to lowa's opposition to UC's motion to designate Iowa claims as corresponding to the Count). October 15, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Reply 2 (to Iowa's opposition to UC Preliminary Motion 2 for Judgment). October 15, 2004.	
*	Patent Interference No. 105,171. Regents of the University of California Reply 3 (to Iowa's Opposition to UC Preliminary Motion 3 for Judgment). October 15, 2004.	

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

	FORM PTO-1449/A and B (modified PTO/SB/08)			APPLICATION NO.: 10/627,413		ATTY. DOCKET NO.: C1039.70079US00	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE:	July 25,2003	CONFIRMATION NO.: 3204		
			APPLICANT:	Krieg et al.			
Sheet 10	of	11	GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le	

	*	Patent Interference No. 105,171. Regents of the University of California Reply 4 (to Iowa's	
	*	Opposition to UC Preliminary Motion 4 for Judgment). October 15, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Reply 5 (to Iowa's	
		Opposition to UC Preliminary Motion 5 for Judgment). October 15, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Reply 6 (to Iowa's	
		opposition to UC Preliminary Motion 6 for judgment). October 15, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Reply 7 (to Iowa's	
		Opposition to UC Preliminary Motion 7 for Benefit). October 15, 2004.	
	*	Patent Interference No. 105,171. Regents of the University of California Reply 8 (to Iowa's	•
		Opposition to UC Preliminary Motion 8 to add additional claims). October 15, 2004.	
	*	Patent Interference No. 105,171. Decision on Motion under 37 CFR §41.125. March 10, 2005.	
_	*	Patent Interference No. 105,171. Judgment and Order. March 10, 2005.	
	*	Patent Interference No. 105,171. Regents of the University of California. Brief of Appellant. July 5, 2005.	
	*	Patent Interference No. 105,171. University of Iowa and Coley Pharmaceutical Group, Inc. Brief of Appellees. August 17, 2005.	
	*	Patent Interference No. 105,171. Regents of the University of California. Reply Brief of Appellant.	
		September 6, 2005.	
	*	Patent Interference No. 105,171. Regents of the University of California. Decision of CAFC. July	
		17, 2006.	
	*	Patent Interference No. 105,526. Krieg Substantive Motion 1 (for unpatentability based on	
		interference estoppel). (Electronically filed, unsigned).	
	*	Patent Interference No. 105,526 Krieg Substantive Motion 2 (for judgment based on inadequate	
		written description and/or enablement). (Electronically filed, unsigned). June 18, 2007.	
	*	Patent Interference No. 105,526. Krieg Contingent Responsive Motion (to add new claims 104 and	
		105). (Electronically filed, unsigned). July 25, 2007.	•
	*	Patent Interference No. 105,526. Krieg Substantive Motion 3 (for judgment based on prior art).	
		(Electronically filed, unsigned). June 18, 2007.	
·	*	Patent Interference No. 105,526. Raz Motion 1 (Unpatentability of Krieg Claims under 35 U.S.C. §	
		112, First Paragraph). (Electronically filed, unsigned). June 18, 2007.	
	*	Patent Interference No. 105,526. Raz Motion 2 (Raising a Threshold Issue of No Interference-in-	
		Fact). (Electronically filed, unsigned). June 18, 2007.	
	*	Patent Interference No. 105,526 Raz Motion 3 (Krieg's Claims are Unpatentable Over Prior Art	
		Under 35 U.S.C. § 102(b)) (Electronically filed, unsigned). June 18, 2007.	
	*	Patent Interference No. 105,526. Raz Motion 4 (To Designate Krieg Claims 46 and 82-84 as	
		Corresponding to Count 1). (Electronically filed, unsigned). June 18, 2007.	
	*	Patent Interference No. 105,526. Raz Responsive Miscellaneous Motion 5 (To revive the Raz	
		Parent Application) (Electronically filed, unsigned) July 25, 2007.	
	*		
		Patent Interference No. 105,526. Raz Contingent Responsive Motion 6 (To Add a New Claim 58) (Electronically filed, unsigned) July 25, 2007.	
	*	Patent Interference No. 105,526. Krieg Opposition 1 (Opposition to Motion for Lack of Enablement	
		and Written Description) (Electronically filed, unsigned) September 10, 2007.	

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1:449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICATION NO.:	10/627,413	ATTY. DOCKET N	io.: C1039.70079US	
			FILING DATE:	July 25,2003	CONFIRMATION	NO.: 3204	
			APPLICANT:	Krieg et al.			
Sheet	11	of	11	GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

*	Patent Interference No. 105,526. Krieg Opposition 2 (to Raz Motion 2) (Electronically filed, unsigned) September 10, 2007.	
*	Patent Interference No. 105,526. Krieg Opposition 3 (To Raz Motion 3) (Electronically filed,	
	unsiged) September 10, 2007.	
*	Patent Interference No. 105,526. Krieg Opposition 4 (Opposition to Motion for Designating Claims	
İ	46 and 82-84 as Corresponding to the Court) (Electronically filed, unsigned) September 10, 2007.	
 *	Patent Interference No. 105,526. Krieg Opposition 6 (Opposition to Raz Contingent Responsive	
	Motion 6) (Electronically filed, unsigned) September 10, 2007.	
*	Patent Interference No. 105,526. Raz Opposition 1 (Opposing Krieg Substantive Motion 1)	
	(Electronically filed, unsigned) September 10, 2007.	
*	Patent Interference No. 105,526. Raz Opposition 2 (Opposing Krieg Substantive Motion 2)	
	(Electronically filed, unsigned) September 10, 2007.	
*	Patent Interference No. 105,526. Raz Opposition 4 (Opposing Krieg Contingent Responsive Motion	
	to Add New Claims 104 and 105) (Electronically filed, unsigned) September 10, 2007.	
*	Patent Interference No. 105,526. Krieg Reply 1 (Reply to Raz opposition 1) October 5, 2007	
*	Patent Interference No. 105,526. Krieg Reply 2 (Reply to Raz opposition 2) October 5, 2007	
*	Patent Interference No. 105,526. Krieg Reply 4 (Reply to Raz opposition 4) October 5, 2007	
*	Patent Interference No. 105,526. Raz Reply 1 (Reply to Krieg opposition 1) October 5, 2007	
*	Patent Interference No. 105,526. Raz Reply 2 (Reply to Krieg opposition 2) October 5, 2007	
 *	Patent Interference No. 105,526. Raz Reply 3 (Reply to Krieg opposition 3) October 5, 2007	
*	Patent Interference No. 105,526. Raz Reply 4 (Reply to Krieg opposition 4) October 5, 2007	
*	Patent Interference No. 105,526. Raz Reply 6 (Reply to Krieg opposition 6) October 5, 2007	
*	Patent Interference No. 105,526. Krieg Miscellaneous Motion 5 (To exclude exhibits 2066, 2070,	
	2071, 2072, 2073, 2074, 2075, 2076 and 2078) October 9, 2007.	
*	Patent Interference No. 105,526. Raz Opposition 5 (Opposing Krieg Miscellaneous Motion 5)	.,
	October 25, 2007.	
*	Patent Interference No. 105,526. Raz Miscellaneous Motion 7 (To exclude evidence) October 19,	
	2007.	
*	Patent Interference No. 105,526. Krieg Opposition 7 (To Raz Miscellaneous Motion 7) October 25,	
	2007.	
*	Patent Interference No. 105,526. Krieg Reply 5 (Reply to Raz opposition 5) October 30, 2007.	
*	Patent Interference No. 105,526. Raz Reply 7 (Reply to Krieg opposition 7) October 30, 2007.	

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/630,319, filed July 31, 2000 and/or 10/187,489, filed July 2, 2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
	21112 001101221021
	ļ.

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.